Acrivon Advances Key Oncology Trials with 2026 Data Readouts on Horizon
Event summary
- Acrivon's ACR-368 Phase 2b study for serous endometrial cancer to deliver interim data in H2 2026, with 52% response rate in serous EC vs. 22% in non-serous.
- ACR-2316 shows durable activity in lung cancers, including SCLC and sqNSCLC, with favorable tolerability profile.
- $97.7M cash runway extends into Q3 2027, supporting multiple clinical milestones.
- Phase 3 trial readiness for ACR-368/PD-1 combination targeted for mid-2026.
The big picture
Acrivon's progress reflects the growing emphasis on precision oncology, particularly in high-unmet-need indications like serous endometrial cancer. The company's AP3 platform positions it as a competitor in the biomarker-driven drug development space, though execution risks remain as it navigates multiple clinical readouts. The $97.7M cash position provides a buffer, but strategic financing decisions will be critical to sustain momentum beyond 2027.
What we're watching
- Clinical Validation
- Whether ACR-368's 52% response rate in serous EC can translate into regulatory approval and commercial success.
- Pipeline Progression
- The pace at which ACR-2316 advances into expansion phases across AP3-identified tumor types.
- Financial Flexibility
- How Acrivon manages its $97.7M cash position to fund operations through 2027 while pursuing multiple value-inflection milestones.
Related topics